###### Strengths and limitations of this study

-   Using standardised methods, this study has for the first time prospectively determined the prevalence, nature and predictors of prescribing errors across three mental health hospitals.

-   Important potential targets were identified for future research to minimise prescribing errors in this setting.

-   While this was a large study, its findings may not be generalisable to inpatient psychiatric care across the National Health Service (NHS).

Introduction {#s1}
============

Medication errors (MEs) and their associated adverse drug events (ADEs) continue to pose significant challenges for healthcare systems worldwide.[@R1] Errors in drug prescribing and administration appear to be the most common MEs.[@R4] In general hospitals, prescribing errors (PEs) are estimated to affect between 2% and 15% of medication orders[@R2] [@R7] and are thought to arise from multiple interacting causes.[@R8] [@R10]

Despite much research activity attempting to understand the frequency, causes and preventive strategies for MEs in general hospital settings, mental health hospitals have been given much less attention.[@R2] [@R13] Published studies of PEs (and/or related ADEs) originate from the UK,[@R9] [@R16] the USA[@R24] and Denmark.[@R28] In common with reviews of general hospital studies,[@R2] differences in study methods, settings and definitions preclude the synthesis of PE data from relevant studies to gain an overall measure of their impact.[@R13] [@R15] [@R29]

Not surprisingly, different ME/ADE identification methods influence the outcome rate.[@R2] [@R14] [@R30] It is accepted that voluntary self-reporting methods such as incident reports grossly underestimate the numbers of MEs that occur when compared to chart review and other detection methods,[@R30] [@R31] which may make subsequent error rates unrepresentative of the practice environment. A number of PE studies carried out in mental health utilised incident/self-reports[@R21] [@R23] with others using a retrospective medication chart review (with or without incident reports/case note review/direct observation).[@R16] [@R17] [@R24] [@R25] [@R28] Prospective identification of PEs in UK psychiatry has most commonly involved pharmacists checking prescription charts over different time periods,[@R9] [@R18] [@R22] yielding error rates of 2.2%[@R18] and 2.4%[@R22] of prescription items checked (two studies did not provide a denominator[@R19] [@R20]) and 31.3% of whole prescriptions checked.[@R9] Between 42.1% and 65% of PEs are administered to patients before correction by the pharmacist.[@R18] [@R20] [@R22]

To the best of our knowledge, no studies have utilised prospective screening of only newly written or omitted prescription items by pharmacists in psychiatry inpatients to find PEs, as seen in general hospitals.[@R7] This design may reduce the possibility of underestimating PE rates if errors which have previously been checked and corrected by healthcare staff prior to examination by data collectors are included.[@R9] [@R18] [@R20] [@R22] In addition, previous studies in psychiatry have not investigated the differences in PE rates or severity between different prescribers and prescribing stages.[@R18] [@R20] [@R22] This study aimed to determine the prevalence, nature and predictors of inpatient PEs in UK mental health settings.

Method {#s2}
======

Settings {#s2a}
--------

Three mental health NHS trusts based in the North West of England took part in the study, including more than 50 inpatient wards across more than 10 hospitals and other smaller facilities. Each trust provided a range of inpatient and community services. On weekdays, clinical pharmacists checked inpatient paper prescription charts written on admission, during patient stay, on chart rewrites (charts were rewritten by prescribers once administration records were complete), on paper leave prescriptions (prescriptions used by patients who could leave the ward temporarily, eg, for a home visit) and on paper discharge prescriptions. Medication lists were reconciled on admission predominantly by pharmacy teams using sources that included the patient, their general practitioner (GP) records and any medication brought into hospital. One study site used an electronic prescription pro forma at discharge. Medications were administered by registered nurses or by patients using self-administration. The pharmacist prescription chart review involved confirming the clarity, completeness and clinical appropriateness of each prescribed item, and occurred daily on some wards (eg, acute adult units) but less frequently on others (eg, long stay forensic units). Where necessary, patients' medical notes were accessed as part of the pharmacists' assessment of prescribing safety. All inpatient units visited by pharmacists on data collection days were included in the study. Outpatient prescriptions were excluded.

Definitions {#s2b}
-----------

The definition of a PE as used in this study has been used extensively in PE research:[@R2] [@R7] [@R18] [@R20] [@R22] 'A clinically meaningful prescribing error occurs when, as a result of a prescribing decision or prescription-writing process, there is an unintentional significant reduction in the probability of treatment being timely and effective, or an increase in the risk of harm when compared with generally accepted practice.'[@R32] This definition was accompanied by a list of situations that should be included and excluded as PEs. However, as the mental health environment differs from typical hospital settings on which this definition was based, we extended its scope to include the following scenarios based on earlier work:[@R18] [@R20] [@R22] (1) prescribing a drug without first registering a patient with the appropriate monitoring service (eg, Clozapine Patient Monitoring Service (CPMS)) and (2) prescribing a drug to treat mental health illness without authorisation from a Mental Health Act form (eg, form T2/T3, Advance Decision).

Data collection {#s2c}
---------------

The process of recording inpatient PEs was based on the UK EQUIP study.[@R7] Twenty-nine clinical pharmacists employed across the study sites identified PEs for all newly prescribed/written or omitted items as part of their routine clinical practice in this setting during a total of 10 data collection days individually selected between January--April 2013. Omitted items were identified after reconciliation on admission or after comparison with earlier inpatient prescribing documentation, and their inclusion in the denominator ensured that pharmacists were able to determine whether items were omitted for a valid clinical reason before recording them as a PE. One data collection day per week was purposively chosen to ensure coverage of all weekdays at least once according to local capacity, with a complete day including the period from 17:00 on the previous day until 17:00 on the assigned data collection day. On Mondays, this period was extended to include prescriptions written from 17:00 the previous Friday throughout the weekend.

Data on the number of newly prescribed or omitted items and the corresponding number of errors were entered onto two standardised forms by pharmacists based on earlier work[@R7] and underwent piloting at one participating site in December 2012. Newly prescribed orders included once only and when required items. Completion of these forms was for research purposes and was outside the pharmacists' normal duties, though time taken on this task was reported to be insignificant during pilot testing. For each PE recorded, pharmacists were asked to record patient information, prescriber grade, stage of patient stay, a potential severity rating (including whether or not the error caused actual patient harm) along with details as to the nature of the PE. Each item checked could be associated with more than one PE.

Pharmacist study co-ordinators based at each site used the same materials to provide training for participating pharmacists which also included question and answer sessions. A standardised guidebook (including definitions of PEs and potential severity assessment categories) was made available to data collectors for use at any point during the study, and co-ordinators made regular contact with data collectors to answer any questions raised.

Error validation {#s2d}
----------------

Validation of all recorded PEs was undertaken by a multidisciplinary panel which comprised one mental health clinical pharmacist (RNK), one consultant pharmacist in medicine and medication safety (SDW) and one consultant psychiatrist (JJV). The errors were reviewed and consensus was reached on (1) whether a genuine PE had occurred, (2) type of error and (3) the potential severity of the error using established criteria.[@R7] PEs that were rated as either potentially clinically significant, serious or life-threatening were considered clinically relevant for patients.

Data analysis {#s2e}
-------------

Descriptive statistics were used to analyse frequency of error categories by prescriber grade and prescribing stage, with additional investigations into the nature of PEs identified (route, severity, type, drug class). Error rates were calculated as a percentage to measure the prevalence of PEs by dividing the number of newly written or omitted prescription items with at least one PE by the total number of these items screened and multiplying the answer by 100. These error rates were then presented with corresponding 95% CIs.

Logistic regression analyses were undertaken to examine (1) predictors of PEs, and (2) predictors of a clinically relevant error (potentially significant, serious or life-threatening) compared to a minor error across different prescribers, prescribing stages and written versus electronic discharge pro forma prescribing. Analysis of potential error severity also involved comparing errors occurring within the central nervous system class of medicines (which includes all psychotropic medicines) versus all other medication classes,[@R33] and comparing different subtypes of PEs that occurred. All logistic regression models were adjusted for clustering at the study site and results presented as adjusted ORs and 95% CIs. All calculations were undertaken using STATA V.12, and p\<0.05 was used to indicate statistical significance.

Results {#s3}
=======

During the study period, 4427 newly written or omitted prescription items were assessed by study pharmacists across the three study sites. A total of 367 PEs were recorded, 79 of which were excluded during review by the expert panel. Good agreement was observed between panel members when reviewing errors, with the most common reason for exclusion at this stage being minor prescription writing incidents such as trivial spelling mistakes, missing information on prescriptions for use when required (eg, no indication, no minimum dosage interval) or writing medication names without using capital letters.

After review by the expert panel, 281 newly prescribed or omitted items were found to be affected by 1 or more PEs, giving an error rate of 6.3% (95% CI 5.6 to 7.1%). Seven prescription items were affected by 2 PEs, giving a total of 288 detected errors. [Table 1](#BMJOPEN2014006084TB1){ref-type="table"} displays PE rates by prescriber and stage of prescribing.

###### 

Summary of prescribing errors by prescriber and prescribing stage

  Prescriber                 Description             Prescribing stage    Total                                                                                        
  -------------------------- ----------------------- -------------------- -------------------- ------------------ -------------------- --------- --------------------- ----------
  FY1**\***                  Items written/omitted   28                   68                   46                 17                   57        0                     **216**
  Errors found               1                       3                    2                    0                  5                    0         **11**                
  Error rate (95% CIs) (%)   3.6 (0.0--10.6%)        4.4 (0.0--9.3%)      4.3 (0.0--10.3%)     0 (NA)             8.8 (1.4--16.2)      --        **5.1 (2.2--8.0)**    
  FY2                        Items written/omitted    95                  124                  179                79                   59        0                     **536**
  Errors found               5                       9                    5                    5                  2                    0         **26**                
  Error rate (95% CIs) (%)   5.3 (0.7--9.8)          7.3 (2.7--11.8)      2.8 (0.4--5.2)       6.3 (0.9--11.7)    3.4 (0.0--8.0)       --        **4.9 (3.0--6.7)**    
  Specialty Trainee†         Items written/omitted   582                  734                  636                114                  270       0                     **2336**
  Errors found               67                      50                   26                   3                  13                   0         **159**               
  Error rate (95% CIs) (%)   11.5 (8.9--14.1)        6.8 (5.0--8.6)       4.1 (2.5--5.6)       2.6 (0.0--5.6)     4.8 (2.3--7.4)       --        **6.8 (5.8--7.8)**    
  Staff Grade Psychiatrist   Items written/omitted    42                  148                  203                18                   38        16                    **465**
  Errors found               10                      9                    5                    2                  4                    0         **30**                
  Error rate (95% CIs) (%)   23.8 (10.8--36.9)       6.1 (2.2--9.9)       2.5 (0.3--4.6)       11.1 (0.0--26.1)   10.5 (0.6--20.4)     0%        **6.5 (4.2--8.7)**    
  Consultant Psychiatrist    Items written/omitted   30                   378                  124                13                   38        3                     **586**
  Errors found               3                       23                   4                    0                  4                    0         **34**                
  Error rate (95% CIs) (%)   10.0 (0.0--20.9)        6.1 (3.7--8.5)       3.2 (0.1--6.3)       0                  10.5 (0.6--20.4)     0%        **5.8 (3.9--7.7)**    
  Pharmacist Prescriber      Items written/omitted   0                    3                    0                  0                    7         0                     **10**
  Errors found               0                       0                    0                    0                  0                    0         **0**                 
  Error rate (95% CIs) (%)   --                      0                    --                   --                 0%                   --        **0**                 
  Nurse Prescriber           Items written/omitted   0                    12                   0                  0                    0         0                     **12**
  Errors found               0                       0                    0                    0                  0                    0         **0**                 
  Error rate (95% CIs) (%)   --                      0                    --                   --                 --                   --        **0**                 
  Unknown Prescriber         Items written/omitted   86                   63                   85                 6                    26        0                     **266**
  Errors found               6                       6                    4                    1                  4                    0         **21**                
  Error rate (95% CIs) (%)   7% (1.6--12.4)          9.5 (2.2--16.8)      4.7 (0.2--9.2)       16.7 (0.0--49.3)   15.4 (1.2--29.5)     --        **7.9 (4.6--11.1)**   
  TOTAL                      Items written/omitted   **863**              **1530**             **1273**           **247**              **495**   **19**                **4427**
  Errors found               **92**                  **100**              **46**               **11**             **32**               **0**     **281**               
  Error rate (95% CIs) (%)   **10.7 (8.6--12.7)**    **6.5 (5.3--7.8)**   **3.6 (2.6--4.6)**   **4.5 (1.9--7)**   **6.5 (4.3--8.6)**   **0%**    **6.3 (5.6--7.1)**    

\*The foundation year (FY) programme corresponds to the first two years of medical training for junior doctors after completion of their undergraduate degree, and is similar to internships or residencies in other countries.

†Specialty trainees include general practitioner trainee (GPST) and psychiatry trainee (CT and ST) medical grades; FY, foundation year.

Orders prescribed on admission to hospital were associated with the highest PE rate (10.7% (95% CI 8.6% to 12.7%)) when compared to items prescribed during hospital stay (6.5% (5.3% to 7.8%)) or at discharge (6.5% (4.3% to 8.6%)). In contrast, items assessed on leave prescriptions (4.5% (1.9% to 7.0%)) and those that were rewritten by prescribers (3.6% (2.6% to 4.6%)) had lower PE rates. Specialty trainees (GP or psychiatry) were responsible for the majority of newly written or omitted items (52.8%) and had the highest PE rate (6.8% (5.8% to 7.8%)) after unknown prescribers (7.9% (4.6% to 11.1%)). Junior foundation year (FY) doctors generally had PE rates lower than their senior colleagues (FY one 5.1% (2.2% to 8.0%); FY two 4.9% (3.0% to 6.7%); staff grade 6.5% (4.2% to 8.7); consultant 5.8% (3.9% to 7.7%)).

Nature of PEs identified {#s3a}
------------------------

The vast majority of identified PEs were associated with the oral route of administration (n=216, 75%) and medicines belonging to the central nervous system class (n=165, 57.3%).

The most common types of PEs were medicines omitted on admission to hospital (n=36, 12.5%), followed by administration times/frequencies that were incorrect or missing (n=33, 11.5%), missing strengths or doses (n=30, 10.4%) and prescribing incorrect drug formulations (n=26, 9.0%). Other common PE subtypes included failing to sign a prescription (n=24), incorrect or missing start dates for prescriptions (n=21) and underdosing (n=20). [Table 2](#BMJOPEN2014006084TB2){ref-type="table"} shows the frequency of all PE subtypes. After review by the multidisciplinary panel, 162 (56.3%), PEs were considered clinically relevant for patients. No PEs were reported by pharmacists to cause actual patient harm. These findings are summarised in [table 3](#BMJOPEN2014006084TB3){ref-type="table"} and a summary of all potentially serious and life-threatening errors is provided in [table 4](#BMJOPEN2014006084TB4){ref-type="table"}.

###### 

Types of prescribing errors

  Type of prescribing error                                                      Subtypes                                             Frequency (%)
  ------------------------------------------------------------------------------ ---------------------------------------------------- ---------------
  Need for drug                                                                  Omission on admission                                36 (12.5)
  Omission of discharge/leave prescription                                       14 (4.9)                                             
  Duplication                                                                    13 (4.5)                                             
  Continuation for longer than needed                                            10 (3.5)                                             
  Omission on rewritten prescription                                             3 (1.0)                                              
  Drug not prescribed but indicated                                              1 (0.3)                                              
  No indication                                                                  1 (0.3)                                              
  Premature discontinuation                                                      0                                                    
  Selection of specific drug                                                     Clinical contra-indication                           9 (3.1)
  Unintentional prescription of drug                                             2 (0.7)                                              
  Continuation after adverse drug reaction                                       0                                                    
  Drug interaction                                                               0                                                    
  Significant allergy                                                            0                                                    
  Select dosage regimen                                                          Underdose                                            20 (6.9)
  Overdose                                                                       12 (4.2)                                             
  No maximum dose                                                                5 (1.7)                                              
  Drug interaction not taken into account                                        1 (0.3)                                              
  Dose/rate mismatch                                                             0                                                    
  No dosage alteration after levels out of range                                 0                                                    
  Daily dose divided incorrectly                                                 0                                                    
  Administration of drug                                                         Administration times/frequencies incorrect/missing   34 (11.8)
  Incorrect formulation                                                          26 (9.0)                                             
  Start date incorrect/missing                                                   21 (7.3)                                             
  Intramuscular instructions incorrect/missing                                   0                                                    
  Incorrect route                                                                0                                                    
  Provide drug product                                                           Strength/dose missing                                30 (10.4)
  No signature                                                                   24 (8.3)                                             
  Product/formulation not specified                                              17 (5.9)                                             
  Prescribed medication not in accordance with Mental Health Act documentation   4 (1.4)                                              
  Route missing                                                                  3 (1.0)                                              
  Controlled drug requirements incorrect/missing                                 1 (0.3)                                              
  Prescription initiated before registration with monitoring service             1 (0.3)                                              

###### 

Severity ratings for identified prescribing errors following multidisciplinary review

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Potential severity criteria              Examples                                                                                                                                                       Frequency (%)                                                                                                                                                   
  ---------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Not clinically relevant                  Minor                                                                                                                                                          Prescription not signed.\                                                                                                                                       126 (43.8)
                                                                                                                                                                                                          No start date on prescription.                                                                                                                                  

  Clinically relevant prescribing errors   Significant                                                                                                                                                    The dose of the drug is too low for a patient with the condition being treated.\                                                                                142 (49.3)
                                                                                                                                                                                                          The wrong route of administration for the condition being treated is ordered, for example, intramuscular depot is prescribed for subcutaneous administration.   

  Serious                                  The dose of the drug would result in serum drug levels in the toxic range, for example, lithium levels 1--2 mmol/L.\                                           19 (6.6)                                                                                                                                                        
                                           The drug orders could exacerbate the patient\'s condition, for example, drug-drug interaction or drug-disease interaction.                                                                                                                                                                                                     

  Life-threatening                         The drug prescribed has a high potential to cause a life-threatening adverse reaction, such as anaphylaxis, in the light of the patient\'s medical history.\   1 (0.3)                                                                                                                                                         
                                           The dose of a potentially life-saving drug is too low for a patient having the disease being treated.                                                                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Descriptions of potentially serious and life-threatening prescribing errors

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Severity                       Patient age   Patient sex            Medication                 Daily dose (intended)                    Indication                           Route of administration   Error description
  ------------------------------ ------------- ---------------------- -------------------------- ---------------------------------------- ------------------------------------ ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Potentially life-threatening   46            Male                   Zuclopenthixol Decanoate   300 mg weekly                            Schizophrenia                        Intramuscular             Clinical Contraindication: Patient prescribed this medication after previous prolonged QTc while taking olanzapine (no QTc values provided). After olanzapine stopped and zuclopenthixol started, no further ECG taken despite receiving two doses of depot (one of which was an increased dose)

  Potentially serious            76            Female                 Moxonidine                 400 µg                                   Hypertension                         Oral                      Clinical contraindication: Medication continued on rewritten prescription despite very low blood pressure recorded.

  Bisoprolol                     5 mg          Hypertension           Oral                       As above---same patient                                                                                 

  Lisinopril                     10 mg         Hypertension           Oral                       As above---same patient                                                                                 

  Doxazosin                      16 mg         Hypertension           Oral                       As above---same patient                                                                                 

  Potentially serious            26            Female                 Quetiapine                 450 mg                                   Personality disorder                 Oral                      Omission on admission: Medicine not prescribed on inpatient admission

  Diazepam                       15 mg         Personality disorder   Oral                       As above---same patient---doses missed                                                                  

  Mirtazapine                    45 mg         Personality disorder   Oral                       As above---same patient---doses missed                                                                  

  Potentially serious            48            Female                 Novorapid insulin          6 units AM                               Diabetes                             Subcutaneous              Dose/strength missing: Insulin dose prescribed as 'U' instead of 'Units' which could have been mistaken for 0 that is, a 10-fold error

  Novorapid insulin              4 units PM    Diabetes               Subcutaneous               As above---same patient                                                                                 

  Novorapid insulin              6 units PM    Diabetes               Subcutaneous               As above---same patient                                                                                 

  Novorapid insulin              4 units PRN   Diabetes               Subcutaneous               As above---same patient                                                                                 

  Potentially serious            78            Female                 Haloperidol                4 mg                                     Psychotic depression                 Oral                      Underdose: Dose prescribed on admission as 500 micrograms twice daily---only 25% of normal dose

  Potentially serious            32            Female                 Sodium valproate           500 mg                                   Epilepsy                             Oral                      Omission on admission: Medication not prescribed on admission---dose missed

  Potentially serious            32            Male                   Enalapril                  20 mg                                    Hypertension                         Oral                      Overdose: Prescribed as 200 mg daily on admission---10 times overdose

  Potentially serious            Unknown       Male                   Cotrimoxazole              960 mg                                   Pneumocystis pneumonia prophylaxis   Oral                      Omission on admission:\
                                                                                                                                                                                                         Failure to prescribe on admission to hospital

  Potentially serious            79            Male                   Risperidone                3 mg                                     Psychosis                            Oral                      Duplication:\
                                                                                                                                                                                                         Dose increased from 1 mg twice daily to 1.5 mg twice daily, but old entry not cancelled.

  Potentially serious            44            Male                   Citalopram                 30 mg                                    Depression                           Oral                      Omission on discharge/leave prescription:\
                                                                                                                                                                                                         Omitted from discharge prescription

  Potentially serious            Unknown       Female                 Clozapine                  Titration                                Psychosis                            Oral                      Clinical contra-indication: despite efforts to slow pace of clozapine dose escalation (due to tachycardia), dose increased by 50 mg daily

  Potentially serious            34            Male                   Sodium valproate MR        1700 mg                                  Seizures                             Oral                      Underdose:\
                                                                                                                                                                                                         On admission, missed off 700 mg morning dose
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Half of the 20 potentially serious or life-threatening PEs involved central nervous system medicines, with the remaining 10 including cardiovascular system (n=5), endocrine system (n=4, all insulin) and anti-infective therapies (n=1). These error types occurred more commonly in female patients (n=14) and most frequently involved clinical contraindications (n=6), omission on admission (n=5) and missing strengths or doses (n=4); 3 female patients accumulated 11 of these errors, with one affected by 4 clinical contraindications, another with 4 with missing strengths/doses and the final patient with 3 drugs omitted on admission. In contrast, 25% of all potentially serious or life-threatening PEs involved injectable administration routes (subcutaneous route (n=4) or intramuscular (n=1) compared with a total of 20/288 (6.9%) overall).

Predictors of PEs {#s3b}
-----------------

Multivariate logistic regression analysis found that specialist trainee registrars (OR 1.23, 95% CI 1.01 to 1.51) and staff grade psychiatrists (OR 1.50 (1.05 to 2.13)) were more likely to make PEs than more junior FY one doctors when controlling for prescribing stage, electronic discharge prescriptions and when clustered for study site (as shown in [table 5](#BMJOPEN2014006084TB5){ref-type="table"}).

###### 

Predictors of (a) error likelihood and (b) potential error severity: multivariate logistic models

  Factor                                                Odds of prescribing error compared to no error   Odds of clinically relevant prescribing error rather than a minor error\*   
  ------------------------------------- --------------- ------------------------------------------------ --------------------------------------------------------------------------- -------------------
  Prescriber                            FY one          Reference                                        Reference                                                                   
  FY two                                0.96            0.84 to 1.11                                     1.83                                                                        0.77 to 4.38
  Specialty Trainee^†^                  **1.23**        **1.01 to 1.51**                                 **2.61**                                                                    **2.11 to 3.22**
  Staff Grade Psychiatrist              **1.50**        **1.05 to 2.13**                                 2.88                                                                        0.70 to 11.83
  Consultant Psychiatrist               1.18            0.71 to 1.95                                     **2.03**                                                                    **1.66 to 2.50**
  Prescribing stage                     During stay     Reference                                        Reference                                                                   
  Admission                             1.81            0.51 to 6.37                                     **5.39**                                                                    **2.72 to 10.69**
  Rewritten item                        **0.52**        **0.33 to 0.82**                                 **2.27**                                                                    **1.72 to 2.99**
  Leave                                 0.66            0.39 to 1.11                                     2.57                                                                        0.74 to 8.95
  Discharge                             **0.87**        **0.79 to 0.97**                                 **4.23**                                                                    **3.68 to 4.87**
  Electronic discharge pro forma item   No              Reference                                        Reference                                                                   
  Yes                                   1.30            0.72 to 2.35                                     0.92                                                                        0.38 to 2.22
  Medication class ‡                    All others      --                                               --                                                                          Reference
  Central Nervous System                --              --                                               0.71                                                                        0.34--1.49
  Prescribing error subcategories §     Need for drug   --                                               --                                                                          Reference
  Selection of specific drug            --              --                                               2.36                                                                        **0.23 to 24.48**
  Select dosage regimen                 --              --                                               **0.44**                                                                    **0.20 to 0.97**
  Administration of drug                --              --                                               **0.17**                                                                    **0.09 to 0.32**
  Provide drug product                  --              --                                               **0.04**                                                                    **0.02 to 0.12**
  Pseudo R squared values               **0.02**        **0.28**                                                                                                                     

\*Potentially clinically relevant prescribing errors (PEs) (either significant, serious or life-threatening) versus minor errors.

**†**Specialty trainees include general practitioner trainee (GPST) and psychiatry trainee (CT and ST) medical grades.

‡no OR for risk of at least one PE as no denominator data collected for medication classes.

§See table 2 for a list of PE subcategories.

Values highlighted in bold are statistically significant (p\<0.05).

When compared to items written or omitted during the patients' stay, prescribers were less likely to make PEs when medication charts were rewritten or when patients were discharged home (OR 0.52 (0.33 to 0.82) and 0.87 (0.79 to 0.97), respectively). Newly written or omitted items on admission showed no differences in risk of PEs (OR 1.81 (0.51 to 6.37)), and nor did items written or omitted for patient leave (OR 0.66 (0.39 to 1.11)) when compared to those screened during patient stay. No difference in risk of PE was observed when discharge prescriptions written on a standard electronic pro forma were compared to handwritten counterparts (OR 1.30 (0.72 to 2.35)).

Predictors of clinically relevant PEs {#s3c}
-------------------------------------

As shown in [table 5](#BMJOPEN2014006084TB5){ref-type="table"}, multivariate logistic regression analysis revealed that more experienced medical staff were more likely to make a clinically relevant PE than their junior counterparts (FY one), with specialty trainee registrars (GP or psychiatry) and consultant psychiatrists being twice as likely to do so (OR 2.61 (2.11 to 3.22) and 2.03 (1.66 to 2.50), respectively).

Patient admission and discharge were associated with a significantly increased risk of making a potentially clinically relevant PE when compared with during stay (OR 5.39 (2.72 to 10.69) and 4.23 (3.68 to 4.87), respectively), with the process of rewriting prescriptions also at significantly higher risk (OR 2.27 (1.72 to 2.99)). No difference in risk was observed when leave prescriptions were compared to those written during patient stay.

When compared with those errors associated with the 'need for drug' PE subcategory, the groups 'select dosage regimen', 'administration of drug' and 'provide drug product' were associated with a lower risk of potentially clinically relevant PEs (OR 0.44 (0.20 to 0.97), 0.17 (0.09 to 0.32), 0.04 (0.02 to 0.12), respectively). The latter two groups in particular were associated with much lower risks; the PE types included in these groups were mostly clerical in origin (eg, missing prescriber signature, see [table 2](#BMJOPEN2014006084TB2){ref-type="table"}).

Neither prescriptions written on a standard electronic pro forma (OR 0.92 (0.38 to 2.22)) nor the central nervous system medication class (OR 0.71 (0.34 to 1.49)) were associated with an increased likelihood of clinically relevant PEs when compared to minor errors.

Discussion {#s4}
==========

Main findings {#s4a}
-------------

This is the first study to prospectively identify the prevalence, nature and predictors of inpatient PEs in mental health hospitals for only newly written or omitted prescription items, finding an overall rate of 6.3% (95% CI 5.6 to 7.1%). Most of the PEs identified related to omissions of drugs on admission to or discharge from hospital as well as missing or incorrect prescription requirements (eg, dose, frequency, signatures, formulations). Over half (56%) of all 288 errors identified were considered to be clinically relevant with the potential to cause patient harm, with 20 (6.9%) being graded as potentially serious or life-threatening. Specialty trainees and staff grade psychiatrists were more likely to make a PE, with specialty trainees and consultants more likely to make a potentially clinically relevant PE. Rewritten and discharge prescription items were significantly less likely to contain a PE than those written during patient stay, but were found to be at higher risk of potentially clinically relevant errors (especially on admission and discharge, where the risk was five and four times that of during stay, respectively). PE subtypes including prescription writing errors were associated with significantly lower risks of potentially clinically relevant PEs when compared to groups which included omitted and duplicated drugs. Electronic prescribing at discharge using a template and the 'central nervous system' drug class (which contains all psychotropic medicines) were found not to be associated with an increased risk of clinically relevant PEs.

Implications of findings {#s4b}
------------------------

Our overall PE rate of 6.3% is higher than the 2.2%[@R18] and 2.4%[@R22] previously reported in UK psychiatric hospitals using the prospective medication chart review, and similar to a median rate of 7/100 medication orders reported in general hospitals worldwide.[@R2] However, differences in the type of prescription items that were assessed (ie, we included only newly omitted and written items), the data collection periods (4 days[@R18] or 5 days[@R22] vs 10 in this study), severity assessments, study settings and year of publication preclude more direct comparisons.[@R2] [@R34] Recent UK based general hospital PE investigations using similar methodology as this study reported higher PE rates,[@R7] [@R8] which may reflect different patient complexities, the working environment, the medicines used (eg, intravenous medicines are rarely used in psychiatry) and the predominant focus on mental health rather than physical health in psychiatry settings. In contrast, retrospective reviews of case notes/medication charts to identify PEs in psychiatry[@R25] yield higher error rates of 15% of error opportunities, although the denominator and setting of this study was different to ours.

The finding that a sizeable proportion of PEs concerned dosing errors or incomplete prescription items has been noted in other studies of PEs in psychiatry,[@R18] [@R20] [@R22] and in general hospitals.[@R2] [@R7] However, while studies in general hospitals also found that the omission of drugs on admission/discharge/rewritten prescriptions was a leading PE subtype,[@R2] [@R7] previous studies in psychiatry did not.[@R18] [@R20] [@R22] Omission of drugs on patient transfer may arise due to the inadequate communication of drug information,[@R8] [@R35] an issue which may affect mental health settings more acutely given the increasing number of community services creating more care transfer interfaces.[@R13] [@R36] [@R37] One UK study found that 69% and 43%, respectively, of hospital admission and postdischarge medicines were affected by a medication discrepancy,[@R17] and more recently studies found that 56.2% of hospital admissions (UK based)[@R38] and 23.3% of discharges (USA based)[@R39] were affected, with the most common types being drug omissions. These studies highlight the importance of medicines reconciliation, a practice which is established in UK mental health hospitals[@R40] and which has shown value across hospital settings.[@R38] [@R40]

Despite the prevalence of drug omission errors during care transfer, the patient admission stage was not associated with significantly higher PE rates than during patient stay in this study, with the rewrite and discharge stages associated with significantly lower risks of PEs. However, errors occurring on admission, rewrite and discharge were more likely to harm patients (considered as clinically significant errors---potential to cause significant, serious or life-threatening harm), which could reflect the fact that errors could cause immediate deterioration in a patient's clinical condition and/or go unnoticed for long periods of time. The clear dangers posed by patient transfer in psychiatry have been recognised nationally in the UK,[@R37] [@R43] though this challenge has received less attention overall than in general hospitals.[@R13] [@R15] [@R36] Future research should seek to clarify the frequency, nature and severity of PEs across and between care interfaces in the mental health setting, as well as investigating further the impact of medicines reconciliation.

This study has indicated that more senior specialty trainees and staff grade psychiatrists are at a significantly increased risk of making a PE when compared to their FY one colleagues. This is in contrast to the EQUIP study, which found that junior doctors were more likely to make PEs.[@R7] The regression analysis also revealed that consultants were at a higher risk of making potentially clinically relevant PEs, along with specialty trainees when compared to FY one doctors. While senior doctor prescribing has not been formerly evaluated in psychiatry in relation to PEs, the bulk of prescribing on admission and discharge (where more clinically significant errors occurred) was carried out by specialty trainees, which may explain why this association was found. Consultant prescribing may be more complex and risky than junior doctor prescribing, with negative perceptions towards prescription rewrites from medical staff noted in research from general hospitals also potentially contributing.[@R11] Future research should investigate in detail the prescribing of more senior clinicians in mental health, as previous studies making similar comparisons did not do so in the context of total prescribing burdens using multivariate regression analysis.[@R18] [@R22]

This study has emphasised the importance of pharmacy teams in the detection and prevention of PEs and associated patient harms in mental health hospitals, as seen elsewhere.[@R9] [@R18] [@R20] [@R22] [@R25] [@R38] Given the important contribution of medicines to avoidable harm in hospitals, the input of pharmacy teams in keeping patients safe should not be underestimated.[@R43]

Our analysis did not reveal any difference in the risk of a PE between electronic and handwritten prescriptions, though this should be viewed with caution as the number of electronically prescribed items in our analysis was low and the nature of this type of prescribing was limited to discharge prescription templates at one study site (ie, no commercially available e-prescribing software was used). Although the benefits of electronic prescribing software should not be overlooked,[@R15] further investigation may be required because, despite important reductions in some errors, the wider effects of electronic prescribing systems on MEs and ADEs are not clear, and in some cases novel PE opportunities may be created.[@R44]

To the best of our knowledge, there have been no published attempts to determine the causes of PEs in inpatient mental health settings despite the growing understanding in general hospitals that these errors involve multiple, interacting antecedents.[@R7] [@R8] [@R10] Although a number of different interventions designed to reduce PEs have been suggested,[@R45] future research should focus on determining the causes of PEs in psychiatry using theoretical frameworks such as Reason\'s Model of Accident Causation[@R46] as recommended previously.[@R13] [@R15] [@R47] Reason\'s model has been used frequently in general hospitals for this purpose,[@R7] [@R10] and such investigations would facilitate measurement of the value of remedial interventions in the psychiatry setting. As a large proportion of care for mental health patients takes place in the community, future studies of PEs could also be carried out in this setting.[@R13] [@R36]

Strengths and limitations {#s4c}
-------------------------

The key strengths of this study are that it used standardised training of data collectors, sought to compare risk of PEs and clinically relevant errors between prescribers and prescribing stages, and collected data on only newly written or omitted items over a range of data collection days so that items were counted only once and the risk of including previously corrected items was minimised.

Although this study was conducted across three sites over a large geographical area, generalisability may be limited when compared to earlier work.[@R22] A combined medication chart and case note review may identify a greater number of PEs,[@R30] so our PE rate may be an underestimate of the true burden of these errors in mental health hospitals. While data collectors were trained to use standardised materials, it is impossible to exclude variation in error detection due to differing workloads,[@R48] vigilance and/or individual clinical experience of collectors.[@R9] [@R22] The rate of false positives was minimised by using a multidisciplinary PE review panel, one senior member of which (SDW) had previously evaluated PEs in a much larger study.[@R7] We did not record separate PE rate data for core medical versus GP specialty trainees or psychotropic versus non-psychotropic medicines, which means that we were unable to compare these different groups.

The fact that unknown prescribers were associated with the highest PE rate (7.9% (4.7--11.1%)) highlights the need to ascertain the identity of prescribers as well as when and where prescribing took place in order to facilitate optimal patient care and rectify mistakes promptly. Prescriber identification becomes an even more critical issue given the more recent emphasis on the importance of feedback to improve prescribing practice and minimise PEs.[@R7] [@R8] [@R45] [@R49]

Conclusion {#s5}
==========

PEs may be more common in mental health hospitals than previously reported, and continue to post a significant challenge to healthcare providers as the majority have the potential to cause patient harm. This study has identified more senior prescribers and care transfer interfaces as potential targets to investigate the burden of these errors in more detail with the aim of formulating remedial approaches. Future work should focus on using theoretical frameworks such as those of human error to investigate the causes of PEs in order to inform the design of interventions aimed at reducing their burden in the psychiatric inpatient setting.
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